Thyritope Biosciences
San Diego · Founded 2014
About Thyritope Biosciences
Thyritope Biosciences is developing therapeutics that target thyroid stimulating auto-antibodies, which are the causative drivers of Graves' hyperthyroidism and Graves' orbitopathy. Graves' disease is an autoimmune disorder caused by antibodies that over-stimulate the thyroid, causing excessive thyroid hormone production. The same antibodies stimulate the tissue around the eyes, resulting in an increase of orbital fat and extra-ocular muscle volume which causes the bulging of the eyes characteristic of Graves' orbitopathy.
Company Facts
- Founded: 2014
- Legal name: Thyritope Biosciences, Inc.
- Operating status: Operating
- Company type: For Profit
- IPO status: Private
- Total funding: $10.0M
- Funding stage: Early Stage Venture
- Last round: Series A (Sep 2014)
Canonical: https://fsome.com/organization/thyritope-biosciences-8277124 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.